Attovia Therapeutics Stock
Attovia Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Tao Fu
- Employees
- 44
- Market cap
- $627 M
- IPO
- 05/08/2026
A clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases using its ATTOBODY biologics platform. The company's lead candidate, ATTO-1310, targets interleukin-31 (IL-31), known as the 'itch cytokine,' for the treatment of chronic pruritic diseases including atopic dermatitis.…
Attovia Therapeutics stock: price history
1D
-7.1%
1W
-15.3%
1M
-38.3%
6M
–
YTD
–
1Y
–
2Y
–
5Y
–
10Y
–
Next earnings date
Next earnings date
02/12/2026 (in 46 days)
Volatility around earnings
Not enough history for an assessment
Ask the agents about Attovia Therapeutics
Analyst assessment of Attovia Therapeutics
PRICE TARGET LOW
US$39.00
CONSENSUS
US$45.33
MEDIAN
US$45.00
PRICE TARGET HIGH
US$52.00
No current analyst ratings available.
Attovia Therapeutics stock metrics
P/E
-14.76
P/B
5.56
EV/EBITDA
-14.5
RETURN ON EQUITY
-18.3%
NET MARGIN
-4,597.1%
DEBT/EQUITY
0.04
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
62.3%
FLOAT SHARES
28,437,037
AVG. DAILY VOLUME (30D)
450,796
Insider transactions (SEC)
WALSH COLIN
WALSH COLIN
WALSH COLIN
WALSH COLIN
WALSH COLIN
Institutional holders
Comparable stocks
Frequently asked questions about Attovia Therapeutics stock
What does Attovia Therapeutics do?
Attovia Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Tao Fu, the company employs around 44 people.
The IPO was on 05/08/2026; the stock trades on NASDAQ under the ticker ATTO.
What do analysts say about Attovia Therapeutics stock?
The average price target is US$45.33, ranging from US$39.00 to US$52.00, with a median of US$45.00.
This is an external assessment, not a statement by Market Jury.
When does Attovia Therapeutics report next?
The next earnings date is 02/12/2026.
Does Attovia Therapeutics pay a dividend?
No, Attovia Therapeutics currently does not pay a dividend.
Which stocks are comparable to Attovia Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Attovia Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Attovia Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.